Yonezawa Atsushi, Matsubara Kazuo
Dept. of Clinical Pharmacology and Therapeutics, Kyoto University Hospital.
Gan To Kagaku Ryoho. 2020 Mar;47(3):397-401.
Several biosimilars have appeared in cancer treatment. They should contribute to the reduction of medical cost. However, in Japan, a suspicion of medical staffs and patients to biosimilars and an obstruction of High-Cost Medical Expense Benefit to the burden reduction of patients suppress the use of biosimilars. Recently, several guidelines declare to promote the use of biosimilars. High-quality biosimilars are also going to be developed by next generation biotechnologies. The positive selection of biosimilars hopefully contribute to patients and national medical economy. In this review, we mention about the current subjects and future prospects of biosimilars.
几种生物类似药已出现在癌症治疗领域。它们应有助于降低医疗成本。然而,在日本,医护人员和患者对生物类似药的怀疑以及高额医疗费补贴对减轻患者负担的阻碍抑制了生物类似药的使用。最近,一些指南宣称要促进生物类似药的使用。高质量的生物类似药也将通过下一代生物技术进行研发。生物类似药的积极选用有望造福患者和国家医疗经济。在本综述中,我们将提及生物类似药的当前问题和未来前景。